Abstract
The new substituted benzamide compound eticlopride ((S)-(-)-5-chloro-3-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamide hydrochloride; FLB 131) has been shown to selectively block the dopamine-D2 receptors in the rat brain. Eticlopride was thus found to inhibit the apomorphine induced syndrome at very low doses (ED50 for inhibition of stereotypies: 200 nmol/kg i.p. and for hyperactivity: 23 nmol/kg i.p.). Similar to other substituted benzamides eticlopride induces a weak form of catalepsy only at high doses (ED50 2.5 umol/kg i.p.). In vitro, the compound was found to inhibit dopamine-D2 receptors very potently (Table 1). For the further characterization of the receptor binding properties eticlopride was radiolabelled using catalytic hydrogenation to high specific radioactivity and was used for in vitro and in vivo receptor binding studies.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1986 The Contributors
About this chapter
Cite this chapter
Hall, H., Köhler, C., Gawell, L. (1986). Eticlopride, a Potent Substituted Benzamide Compound Useful for the Labelling of Rat Central Dopamine-D2 Receptors in vitro and in vivo. In: Woodruff, G.N., Poat, J.A., Roberts, P.J. (eds) Dopaminergic Systems and their Regulation. Satellite Symposia of the IUPHAR 9th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-07431-0_29
Download citation
DOI: https://doi.org/10.1007/978-1-349-07431-0_29
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-07433-4
Online ISBN: 978-1-349-07431-0
eBook Packages: MedicineMedicine (R0)